Time New York: Sun 19 Aug 07:47 am  |  Save 15% on H&R Block Online

  
caticonslite_bm_alt

Express Scripts (ESRX) Soars: Stock Adds 8.6% in Session

Zacks

Express Scripts Holding Company ESRX was a big mover last session, as the company saw its shares rise nearly 9% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This breaks the recent trend of the company, as the stock is now trading above the volatile price range of $72.89 to $78.64 in the past one-month time frame.

The stock gained after Cigna agreed to buy the company, including its debt, for $67 billion.

The company has seen two positive estimate revisions in the past few weeks, while its Zacks Consensus Estimate for the current quarter has also moved higher over the past few weeks, suggesting that more solid trading could be ahead for Express Scripts. So make sure to keep an eye on this stock going forward to see if this recent jump can turn into more strength down the road.

Express Scripts currently has a Zacks Rank #2 (Buy) while its Earnings ESP is negative.


Another stock worth considering in the Medical Services industry is Healthways, Inc. TVTY which carries a Zacks Rank #1 (Strong Buy).You can see the complete list of today’s Zacks #1 Rank stocks here.

Is ESRX going up? Or down? Predict to see what others think: Up or Down

Don’t Even Think About Buying Bitcoin Until You Read This

The most popular cryptocurrency skyrocketed last year, giving some investors the chance to bank 20X returns or even more. Those gains, however, came with serious volatility and risk. Bitcoin sank 25% or more 3 times in 2017.

Zacks has just released a new Special Report to help readers capitalize on the explosive profit potential of Bitcoin and the other cryptocurrencies with significantly less volatility than buying them directly.

See 4 crypto-related stocks now >>


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

To read this article on Zacks.com click here.

Zacks Investment Research
<-- You can share this post with your network,
or give us your opinion and leave a comment.
Be sure to check our RSS feeds for updates.

Get AutoBlogged